Complement system activation and endothelial dysfunction in patients with age-related macular degeneration (AMD): Possible relationship between AMD and atherosclerosis

Acta Ophthalmologica

Volumn 90, Issue 8, 2012, Pages 695-703

  MacHalińska, Anna ^a   Kawa, Miłosz P ^a   Marlicz, Wojciech ^a   MacHaliński, Bogusław ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

age related macular degeneration; atherosclerosis; complement system; pathogenesis

Indexed keywords

ANGIOGENESIS INHIBITOR; ARC 1905; COMPLEMENT COMPONENT C5 INHIBITOR; COMPLEMENT FACTOR H; COMPLEMENT INHIBITOR; COMPSTATIN; ECULIZUMAB; IMMUNOSUPPRESSIVE AGENT; JPE 1375; PEXELIZUMAB; POT 4; RANIBIZUMAB; RECOMBINANT COMPLEMENT FACTOR H; RECOMBINANT PROTEIN; TA 106; TP 10; TT 30; UNCLASSIFIED DRUG;

ARTERIOSCLEROSIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL DAMAGE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG EFFICACY; DRUG RESEARCH; DRUSEN; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GENETIC POLYMORPHISM; GEOGRAPHIC ATROPHY; HISTOPATHOLOGY; HUMAN; INFLAMMATION; METABOLIC STRESS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OXIDATIVE STRESS; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SMOKING; SUBRETINAL NEOVASCULARIZATION; VASCULAR ENDOTHELIUM;

ANIMALS; ATHEROSCLEROSIS; COMPLEMENT ACTIVATION; COMPLEMENT FACTOR H; COMPLEMENT SYSTEM PROTEINS; ENDOTHELIUM, VASCULAR; HUMANS; MACULAR DEGENERATION; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84870549384     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2011.02295.x     Document Type: Review

References (88)

1. Augood CA, Vingerling JR, De Jong PT, et al., (2006): Prevalence of age-related maculopathy in older Europeans: the European Eye Study. Arch Ophthalmol 124: 529-535.
2. Booij JC, Baas DC, Beisekeeva J, Gorgels TG, &, Bergen AA, (2010): The dynamic nature of Bruch's membrane. Prog Retin Eye Res 29: 1-18.
3. Boos CJ, Lip GY, &, Blann AD, (2006): Circulating endothelial cells in cardiovascular disease. J Am Coll Cardiol 4: 1538-1547.
4. Bora PS, Sohn JH, Cruz JMC, et al., (2005): Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J Immunol 174: 491-497.
5. Brantley MA, Edelstein SL, King JM, Apte RS, Kymes SM, &, Shiels A, (2007a): Clinical phenotypes associated with the complement factor H Y402H variant in age-related macular degeneration. Am J Ophthalmol 144: 404-408.
6. Brantley MA, Fang AM, King JM, Tewari A, Kymes SM, &, Shiels A, (2007b): Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 114: 2168-2173.
7. Ciulla T, Harris A, &, Chung H, (1999): Color Doppler imaging discloses reduced ocular blood flow velocities in non-exudative age-related macular degeneration. Am J Ophthalmol 128: 75-80.
8. Clark SJ, Perveen R, Hakobyan S, Morgan BP, Sim RB, Bishop PN, &, Day AJ, (2010): Impaired binding of the AMD-associated complement factor H 402H allotype to Bruch's membrane in human retina. J Biol Chem 285: 30192-30202.
9. Connell PP, Keane PA, O'Neill EC, Altaie RW, Loane E, Neelam K, Nolan JM, &, Beatty S, (2009): Risk factors for age-related maculopathy. J Ophthalmol 2009: 1-39.
10. Curcio CA, Presley JB, Malek G, Medeiros NE, Avery DV, &, Kruth HS, (2005): Esterified and unesterified cholesterol in drusen and basal deposits of eyes with age-related maculopathy. Exp Eye Res 81: 731-741.
11. Di Stefano R, Felice F, &, Balbarini A, (2009): Angiogenesis as risk factor for plaque vulnerability. Curr Pharm Des 15: 1095-1106.
12. Donoso LA, Kim D, Frost A, Callahan A, &, Hageman G, (2006): The role of inflammation in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 51: 137-152.
13. Duan Y, Mo J, Klein R, Scott IU, Lin HM, Caulfield J, Patel M, &, Liao D, (2007): Age-related macular degeneration is associated with incident myocardial infarction among elderly Americans. Ophthalmology 114: 732-737.
14. Edwards AO, Ritter R, Abel KJ, Manning A, Panhuysen C, &, Farrer LA, (2005): Complement factor H polymorphism and age-related macular degeneration. Science 308: 421-424.
15. Ennis S, Jomary C, Mullins R, Cree A, Chen X, &, Macleod A, (2008): Association between the SERPING1 gene and age-related macular degeneration: a two-stage case-control study. Lancet 372: 1828-1834.
16. Erdbruegger U, Haubitz M, &, Woywodt A, (2006): Circulating endothelial cells: a novel marker of endothelial damage. Clin Chim Acta 373: 17-26.
17. Eyries M, Collins T, &, Khachigian LM, (2004): Modulation of growth factor gene expression in vascular cells by oxidative stress. Endothelium 11: 133-139.
18. Gehrs KM, Anderson DH, Johnson LV, &, Hageman GS, (2006): Age-related macular degeneration-emerging pathogenetic and therapeutic concepts. Ann Med 38: 450-471.
19. Gold B, Merriam JE, Zernant J, et al., (2006): Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet 38: 458-462.
20. Grunwald J, Hariprasad S, DuPont J, Maguire M, Fine S, Brucker A, Maguire A, &, Ho A, (1998): Foveal choroidal blood flow in age-related macular degeneration (AMD). Invest Ophthalmol Vis Sci 39: 385-390.
21. Grunwald J, Metelitsina T, DuPont J, Ying G-S, &, Maguire M, (2005): Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. Invest Ophthalmol Vis Sci 46: 1033-1038.
22. Guthikonda S, &, Haynes WG, (2006): Homocysteine: role and implications in atherosclerosis. Curr Atheroscler Rep 8: 100-106.
23. Hageman GS, Luthert PJ, Chong NHV, Johnson LV, Anderson DH, &, Mullins RF, (2001): An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 20: 705-732.
24. Hageman GS, Anderson DH, Johnson LV, et al., (2005): A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A 102: 7227-7232.
25. Haines JL, Hauser MA, Schmidt S, et al., (2005): Complement factor H variant increases the risk of age-related macular degeneration. Science 308: 419-421.
26. Hu Y, Davison F, Zhang ZG, &, Xu Q, (2003): Endothelial replacement and angiogenesis in arteriosclerotic lesions of allografts are contributed by circulating progenitor cells. Circulation 108: 3122-3127.
27. Hu CC, Ho JD, &, Lin HC, (2010): Neovascular age-related macular degeneration and the risk of stroke: a 5-year population-based follow-up study. Stroke 41: 613-617.
28. Hunting CB, Noort WA, &, Zwaginga JJ, (2005): Circulating endothelial (progenitor) cells reflect the state of the endothelium: vascular injury, repair and neovascularization. Vox Sang 88: 1-9.
29. Johnson LV, Leitner WP, Staples MK, &, Anderson DH, (2001): Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp Eye Res 73: 887-896.
30. Johnson PT, Betts KE, Radeke MJ, Hageman GS, Anderson DH, &, Johnson LV, (2006): Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid. Proc Natl Acad Sci U S A 14: 17456-17461.
31. Jylhävä J, Eklund C, Jylhä M, Hervonen A, Lehtimäki T, Karhunen P, &, Hurme M, (2009a): Complement factor H 402His variant confers an increased mortality risk in Finnish nonagenarians: the Vitality 90+ study. Exp Gerontol 44: 297-299.
32. Jylhävä J, Eklund C, Pessi T, et al., (2009b): Genetics of C-reactive protein and complement factor H have an epistatic effect on carotid artery compliance: the Cardiovascular Risk in Young Finns Study. Clin Exp Immunol 155: 53-58.
33. Kardys I, Klaver CC, Despriet DD, et al., (2006): A common polymorphism in the complement factor H gene is associated with increased risk of myocardial infarction: the Rotterdam Study. J Am Coll Cardiol 47: 1568-1575.
34. Kardys I, de Maat MP, Klaver CC, Despriet DD, Uitterlinden AG, Hofman A, de Jong PT, &, Witteman JC, (2007): Usefulness of combining complement factor H and C-reactive protein genetic profiles for predicting myocardial infarction (from the Rotterdam Study). Am J Cardiol 100: 646-648.
35. Klein RJ, Zeiss C, Chew EY, et al., (2005): Complement factor H polymorphism in age-related macular degeneration. Science 308: 385-389.
36. Klein R, Klein BE, Knudtson MD, et al., (2007): Subclinical atherosclerotic cardiovascular disease and early age-related macular degeneration in a multiracial cohort: the Multiethnic Study of Atherosclerosis. Arch Ophthalmol 125: 534-543.
37. Laine M, Jarva H, Seitsonen S, et al., (2007): Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol 178: 3831-3836.
38. Lazar HL, Bokesch PM, van Lenta F, Fitzgerald C, Emmett C, Marsh HC Jr, &, Ryan U, (2004): Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass. Circulation 110: II274-II279.
39. Liao D, Mo J, Duan Y, Klein R, Scott IU, Huang KA, &, Zhou H, (2008): Is age-related macular degeneration associated with stroke among elderly americans? Open Ophthalmol J 2: 37-42.
40. Lip PL, Blann AD, Hope-Ross M, Gibson JM, &, Lip GY, (2001): Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology and endothelial dysfunction. Ophthalmology 108: 705-710.
41. MachaliŃska A, Dziedziejko V, Mozolewska-Piotrowska K, Karczewicz D, Wiszniewska B, &, MachaliŃski B, (2009): Elevated plasma levels of C3a complement compound in the exudative form of age-related macular degeneration. Ophthalmic Res 42: 54-59.
42. MachaliŃska A, Safranõw K, Dziedziejko V, et al., (2011): Different populations of circulating endothelial cells in patients with the exudative form of age-related macular degeneration: a novel insight into pathogenesis. Invest Ophthalmol Vis Sci 52: 93-100.
43. Massa M, Rosti V, Ferrario M, et al., (2005): Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood 105: 199-206.
44. Miller-Kasprzak E, &, JagodziŃski PP, (2007): Endothelial progenitor cells as a new agent contributing to vascular repair. Arch Immunol Ther Exp 55: 247-259.
45. Mooijaart SP, Koeijvoets KM, Sijbrands EJ, Daha MR, &, Westendorp RG, (2007): Complement factor H polymorphism Y402H associates with inflammation, visual acuity, and cardiovascular mortality in the elderly population at large. Exp Gerontol 42: 1116-1122.
46. Nakashima Y, Wight TN, &, Sueishi K, (2008): Early atherosclerosis in humans: role of diffuse intimal thickening and extracellular matrix proteoglycans. Cardiovasc Res 79: 14-23.
47. Nguyen-Khoa BA, Goehring EL, Werther W, Gower EW, Do DV, &, Jones JK, (2008): Hospitalized cardiovascular diseases in neovascular age-related macular degeneration. Arch Ophthalmol 126: 1280-1286.
48. Ni Z, &, Hui P, (2009): Emerging pharmacologic therapies for wet age-related macular degeneration. Ophthalmologica 223: 401-410.
49. Nicaud V, Francomme C, Ruidavets JB, et al., (2007): Lack of association between complement factor H polymorphisms and coronary artery disease or myocardial infarction. J Mol Med (Berl) 85: 771-775.
50. Niculescu F, &, Rus H, (2001): Mechanisms of signal transduction activated by sublytic assembly of terminal complement complexes on nucleated cells. Immunol Res 24: 191-199.
51. Niculescu F, &, Rus H, (2004): The role of complement activation in atherosclerosis. Immunol Res 30: 73-80.
52. Nozaki M, Raisler BJ, Sakurai E, et al., (2006): Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A 103: 2328-2333.
53. Palikhe A, Sinisalo J, Seppänen M, Haario H, Meri S, Valtonen V, Nieminen MS, &, Lokki ML, (2007): Serum complement C3/C4 ratio, a novel marker for recurrent cardiovascular events. Am J Cardiol 99: 890-895.
54. Parker C, (2009): Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 373: 759-767.
55. Reynolds R, Hartnett ME, Atkinson JP, Giclas PC, Rosner B, &, Seddon JM, (2009): Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest Ophthalmol Vis Sci 50: 5818-5827.
56. Ricklin D, &, Lambris JD, (2008): Compstatin: a complement inhibitor on its way to clinical application. Adv Exp Med Biol 632: 273-292.
57. Rohrer B, Long Q, Coughlin B, et al., (2009): A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration. Invest Ophthalmol Vis Sci 50: 3056-3064.
58. Schaumberg DA, Christen WG, Buring JE, Glynn RJ, Rifai N, &, Ridker PM, (2007): High-sensitivity C-reactive protein, other markers of inflammation, and the incidence of macular degeneration in women. Arch Ophthalmol 125: 300-305.
59. Schepers A, de Vries MR, van Leuven CJ, Grimbergen JM, Holers VM, Daha MR, van Bockel JH, &, Quax PHA, (2006): Inhibition of complement component C3 reduces vein graft atherosclerosis in apolipoprotein E3-Leiden transgenic mice. Circulation 114: 2831-2838.
60. Schnatbaum K, Locardi E, Scharn D, Richter U, Hawlisch H, &, Knolle J, (2006): Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett 16: 5088-5092.
61. Scholl HP, Charbel Issa P, Walier M, et al., (2008): Systemic complement activation in age-related macular degeneration. PLoS ONE 3: e2593.
62. Seddon JM, George S, Rosner B, &, Klein ML, (2006): CFH gene variant, Y402H, and smoking, body mass index, environmental associations with advanced age-related macular degeneration. Hum Hered 61: 157-165.
63. Seifert PS, &, Hansson GK, (1989): Complement receptors and regulatory proteins in human atherosclerotic lesions. Arteriosclerosis 9: 802-811.
64. Seifert PS, Hugo F, Hansson GK, &, Bhakdi S, (1989): Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits. Lab Invest 60: 747-754.
65. Shagdarsuren E, Bidzhekov K, Djalali-Talab Y, et al., (2008): C1-esterase inhibitor protects against neointima formation after arterial injury in atherosclerosis-prone mice. Circulation 117: 70-78.
66. Sivaprasad S, Bailey TA, &, Chong VN, (2005): Bruch's membrane and the vascular intima: is there a common basis for age-related changes and disease? Clin Experiment Ophthalmol 33: 518-523.
67. Sivaprasad S, Adewoyin T, Bailey TA, Dandekar SS, Jenkins S, Webster AR, &, Chong NV, (2007): Estimation of systemic complement C3 activity in age-related macular degeneration. Arch Ophthalmol 125: 515-519.
68. Smith W, Mitchell P, Leeder SR, &, Wang JJ, (1998): Plasma fibrinogen levels, other cardiovascular risk factors, and age-related maculopathy: the Blue Mountains Eye Study. Arch Ophthalmol 116: 583-587.
69. Spraul CW, Lang GE, Grossniklaus HE, &, Lang GK, (1999): Histologic and morphometric analysis of the choroid, Bruch's membrane, and retinal pigment epithelium in postmortem eyes with age-related macular degeneration and histologic examination of surgically excised choroidal neovascular membranes. Surv Ophthalmol 44: S10-S32.
70. Stark K, Neureuther K, Sedlacek K, et al., (2007): The common Y402H variant in complement factor H gene is not associated with susceptibility to myocardial infarction and its related risk factors. Clin Sci (Lond) 113: 213-218.
71. Sun C, Klein R, &, Wong TY, (2009): Age-related macular degeneration and risk of coronary heart disease and stroke: the Cardiovascular Health Study. Ophthalmology 116: 1913-1919.
72. Széplaki G, Varga L, Füst G, &, Prohászka Z, (2009): Role of complement in the pathomechanism of atherosclerotic vascular diseases. Mol Immunol 46: 2784-2793.
73. Tamai K, Spaide RF, Ellis EA, Iwabuchi S, Ogura Y, &, Armstrong D, (2002): Lipid hydroperoxide stimulates subretinal choroidal neovascularization in the rabbit. Exp Eye Res 74: 301-308.
74. Tan JS, Mitchell P, Smith W, &, Wang JJ, (2007): Cardiovascular risk factors and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology 114: 1143-1150.
75. Tan JS, Wang JJ, Liew G, Rochtchina E, &, Mitchell P, (2008): Age-related macular degeneration and mortality from cardiovascular disease or stroke. Br J Ophthalmol 92: 509-512.
76. Umemura T, Soga J, Hidaka T, et al., (2008): Aging and hypertension are independent risk factors for reduced number of circulating endothelial progenitor cells. Am J Hypertens 21: 1203-1209.
77. Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, &, Stahl GL, (1998): Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 97: 2259-2267.
78. Verrier ED, Shernan SK, Taylor KM, et al., (2004): Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA 291: 2319-2327.
79. Vine AK, Stader J, Branham K, Musch DC, &, Swaroop A, (2005): Biomarkers of cardiovascular disease as risk factors for age-related macular degeneration. Ophthalmology 112: 2076-2080.
80. Vingerling JR, Dielemans I, Bots ML, Hofman A, Grobbee DE, &, De Jong PT, (1995): Age-related macular degeneration is associated with atherosclerosis. Am J Epidemiol 15: 404-409.
81. Vischer UM, (2006): Von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost 4: 1186-1193.
82. Volcik KA, Ballantyne CM, Braun MC, Coresh J, Mosley TH, &, Boerwinkle E, (2008): Association of the complement factor H Y402H polymorphism with cardiovascular disease is dependent upon hypertension status: the ARIC study. Am J Hypertens 21: 533-538.
83. Von Leithner PL, Kam JH, Bainbridge J, Catchpole I, Gough G, Coffey P, &, Jeffery G, (2009): Complement factor h is critical in the maintenance of retinal perfusion. Am J Pathol 175: 412-421.
84. Whitehead AJ, Mares JA, &, Danis RP, (2006): Macular pigment: a review of current knowledge. Arch Ophthalmol 124: 1038-1045.
85. Wong TY, Klein R, Sun C, et al., (2006): Age-related macular degeneration and risk for stroke. Ann Intern Med 18: 98-106.
86. Wu KH, Tan AG, Rochtchina E, Favaloro EJ, Williams A, Mitchell P, &, Wang JJ, (2007): Circulating inflammatory markers and hemostatic factors in age-related maculopathy: a population-based case-control study. Invest Ophthalmol Vis Sci 48: 1983-1988.
87. Yates JR, Sepp T, Matharu BK, et al., (2007): Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med 357: 553-561.
88. Zee RY, Diehl KA, &, Ridker PM, (2006): Complement factor H Y402H gene polymorphism, C-reactive protein, and risk of incident myocardial infarction, ischaemic stroke, and venous thromboembolism: a nested case-control study. Atherosclerosis 187: 332-335.